Cargando…

Maintenance of elderly AML patients with androgens

Detalles Bibliográficos
Autores principales:	Pigneux, Arnaud, Béné, Marie C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5689557/ https://www.ncbi.nlm.nih.gov/pubmed/29156667 http://dx.doi.org/10.18632/oncotarget.21447

Ejemplares similares

In-depth time-dependent analysis of the benefit of allo-HSCT for elderly patients with CR1 AML: a FILO study
por: Devillier, Raynier, et al.
Publicado: (2022)

Maintenance Therapy in AML
por: Reville, Patrick K., et al.
Publicado: (2021)

Adjunction of a fish oil emulsion to cytarabine and daunorubicin induction chemotherapy in high-risk AML
por: Gyan, Emmanuel, et al.
Publicado: (2022)

How old is old: the beginning of a new era for therapeutic challenges for elderly patients with AML
por: Kim, Hee-Je
Publicado: (2014)

Cost comparison of post-remission strategies in younger and older AML patients in France
por: Mounie, Michael, et al.
Publicado: (2023)

Long-term decitabine/retinoic acid maintenance treatment in an elderly sAML patient with high-risk genetics
por: Javorniczky, Nora Rebeka, et al.
Publicado: (2023)

Maintenance therapy for AML after allogeneic HCT
por: Nayak, Rahul K., et al.
Publicado: (2022)

Impact of CNA on AML prognosis
por: Gonzales, Fanny, et al.
Publicado: (2017)

Targeting glutamine uptake in AML
por: Jacque, Nathalie, et al.
Publicado: (2014)

AML treatment in older adults
por: Sehgal, Alison, et al.
Publicado: (2015)

Outcomes of Antifungal Prophylaxis in High-Risk Haematological Patients (AML under Intensive Chemotherapy): The SAPHIR Prospective Multicentre Study
por: Gangneux, Jean-Pierre, et al.
Publicado: (2020)

Allogenic Stem Cell Transplantation Abrogates Negative Impact on Outcome of AML Patients with KMT2A Partial Tandem Duplication
por: Antherieu, Gabriel, et al.
Publicado: (2021)

UCB HCT in FLT3+ AML
por: Ustun, Celalettin, et al.
Publicado: (2017)

In quest for leukemia initiating cells in AML
por: De Grandis, Maria, et al.
Publicado: (2018)

HLX in AML: novel prognostic and therapeutic target
por: Pandolfi, Ashley, et al.
Publicado: (2012)

Phospholipid metabolism regulates AML growth and stemness
por: Xu, Mingjing, et al.
Publicado: (2019)

Biological and Clinical Significance of Androgens and Androgen Receptor in Prostate Cancer
por: Koochekpour, Shahriar
Publicado: (2014)

IRAK1: oncotarget in MDS and AML
por: Beverly, Levi J., et al.
Publicado: (2014)

Targeting cistrome and dysregulated transcriptome of post-MPN sAML
por: Verstovsek, Srdan, et al.
Publicado: (2017)

Unsupervised Flow Cytometry Analysis Allows for an Accurate Identification of Minimal Residual Disease Assessment in Acute Myeloid Leukemia
por: Vial, Jean Philippe, et al.
Publicado: (2021)

Maintenance Therapy With Interleukin-2 for Childhood AML: Results of ELAM02 Phase III Randomized Trial
por: Petit, Arnaud, et al.
Publicado: (2018)

Risk of infection in elderly patients with AML and MDS treated with hypomethylating agents
por: Livio, Pagano, et al.
Publicado: (2018)

Azacitidine Post-Remission Therapy for Elderly Patients with AML: A Randomized Phase-3 Trial (QoLESS AZA-AMLE)
por: Oliva, Esther Natalie, et al.
Publicado: (2023)

p53 pathway dysfunction in AML: beyond TP53 mutations
por: Post, Sean M., et al.
Publicado: (2017)

Early detection of WT1 measurable residual disease identifies high-risk patients, independent of transplantation in AML
por: Lambert, Juliette, et al.
Publicado: (2021)

Peripheral levels of monocytic myeloid‐derived suppressive cells before and after first induction predict relapse and survivals in AML patients
por: Peterlin, Pierre, et al.
Publicado: (2022)

Maintenance therapy with alternating azacitidine and lenalidomide in elderly fit patients with poor prognosis acute myeloid leukemia: a phase II multicentre FILO trial
por: Hunault-Berger, M, et al.
Publicado: (2017)

Androgen resistance in prostate cancer
por: Waxman, J, et al.
Publicado: (2008)

Hif-1α and Hif-2α synergize to suppress AML development but are dispensable for disease maintenance
por: Vukovic, Milica, et al.
Publicado: (2015)

Coordinate PI3K pathway and Bcl-2 family disruption in AML
por: Bose, Prithviraj, et al.
Publicado: (2012)

The ubiquitin-activating enzyme, UBA1, as a novel therapeutic target for AML
por: Barghout, Samir H., et al.
Publicado: (2018)

Survival outcomes of hypomethylating agents maintenance therapy in new diagnosed AML patients: Real experience data
por: Karakus, Volkan, et al.
Publicado: (2022)

Androgens in rheumatoid arthritis: when are they effectors?
por: Cutolo, Maurizio
Publicado: (2009)

Androgen Deprivation Therapy and Cardiovascular Risk
por: Mourmouris, Panagiotis, et al.
Publicado: (2012)

Maintenance of Certification
por: Kavic, Michael S.
Publicado: (2009)

Maintenance and Restoration of Spermatogenesis in Hypophysectomized Rhesus Monkeys by Androgen Administration
por: Smith, Philip E.
Publicado: (1944)

Zebrafish androgen receptor is required for spermatogenesis and maintenance of ovarian function
por: Yu, Guangqing, et al.
Publicado: (2018)

Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia
por: Roboz, Gail J, et al.
Publicado: (2016)

Fisetin as an adjuvant treatment in prostate cancer patients receiving androgen-deprivation therapy
por: Lorenzo, Giuseppe Di, et al.
Publicado: (2022)

Maintenance of Certification and Competency
por: Kavic, Michael S.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_39ibatg04o7fo1judmlj2mvavc